Join the Oncology Voice Network. Join for Free
Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations
ASCO VF ESMO MCBS gastrointestinal malignancies anticancer drugs

Anticancer drugs approved by the Food and Drug Administration for gastrointestinal malignancies: Clinical benefit and price considerations


Share This Article


Summary

  • Drugs approved between 2006 and 2017 were analyzed.
  • Clinical benefit was measured using ESMO Magnitude of Clinical Benefit Scale and ASCO Value Framework.
  • 16 GI cancer drugs received FDA approval for 24 indications, including various drug classes such as monoclonal antibodies, oral targeted therapies, immunotherapeutics, cytotoxic chemotherapies, and recombinant fusion proteins.
  • 82% of supporting trials reported an overall survival benefit of less than 3 months with no significant improvement in quality of life.
  • Only 21% of the approved indications met ESMO's threshold for substantial clinical benefit.
  • Median total drug price (TDP) for oral targeted therapies and immunotherapeutics was significantly higher compared to cytotoxic chemotherapies.
  • The TDP did not correlate with clinical benefit scores.

By 2020, the cost of cancer care in the United States is expected to reach $158 billion US dollars.1 Pharmaceutical drugs are the fastest growing aspect of US health care spending, with oncology treatments amounting to nearly $37.8 billion in 2015. Over the past decade, the average monthly price of oncology drugs more than doubled, from $7 103 to $15 535 USD. Concerns arise as the unprecedented increase in price of new anticancer drugs seem disproportionate to the clinical benefit they produce.

To address the growing disconnect between clinical benefit and cost, various frameworks have been developed by organizations including the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO). The ASCO value framework (VF) was designed to standardize the assessment of value for new anticancer treatment to guide decision-making by physicians and patients. ESMO intends to use the Magnitude of Clinical Benefit Scale (MCBS) to select anti-cancer therapies that offer the greatest benefit, and prioritize their drug funding across the European Union. Notably, more than half of the accelerated US Food and Drug Administration (FDA) approval indications of new anticancer drugs were based on single–arm studies and could not be assessed with the original ESMO MCBS; however these can now be evaluated with ESMO MCBS version 1.1...

 

Click for Source
ASCO VF, ESMO MCBS, gastrointestinal malignancies, anticancer drugs,

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Article
Early phase clinical trial played a critical role in the Food and Drug Administration-approved indications for targeted anticancer drugs: a cross-sectional study from 2012 to 2021
OVN Avatar Yafang Huanga, Weiyi Xiongb, Jingwei Zhaoa, Wentao Lia, Li Mac, Hao Wua

Early phase clinical trial played a critical role in the Food and Drug Administration-approved indications for targeted anticancer drugs: a cross-sectional study from 2012 to 2021

Article
Cost per Event Averted in Cancer Trials in the Adjuvant Setting From 2018 to 2022
OVN Avatar Idine Mousavi, BA; Timothée Olivier, MD; Vinay Prasad, MD, MPH

Cost per Event Averted in Cancer Trials in the Adjuvant Setting From 2018 to 2022

Press Release
Visionaries Behind Oncology Voice Network: Dr. Ramin Farhood & Dr. Kirk Shepard
OVN Avatar OVN Staff

Visionaries Behind Oncology Voice Network: Dr. Ramin Farhood & Dr. Kirk Shepard

Article
Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?
OVN Avatar Omer Ben‐Aharon, Racheli Magnezi, Moshe Leshno, and Daniel A. Goldstein

Median Survival or Mean Survival: Which Measure Is the Most Appropriate for Patients, Physicians, and Policymakers?

Press Release
Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes
OVN Avatar OVN Staff

Announcing the Launch of Voices of Oncology: A Landmark Collaboration with Forbes

Press Release
Introducing OncologyVoiceNetwork.com
OVN Avatar OVN Staff

Introducing OncologyVoiceNetwork.com

Explore OVN